Abstract
We previously reported a phase 2 trial of 69 patients with newly diagnosed anaplastic or aggressive oligodendroglioma who were treated with intensive procarbazine, CCNU (lomustine), and vincristine (PCV) followed by high-dose thiotepa with autologous stem cell rescue. This report summarizes the long-term follow-up of the cohort of 39 patients who received high-dose thiotepa with autologous stem cell support. Thirty-nine patients with a median age of 43 (range, 18-67) and a median KPS of 100 (range, 70-100) were treated. Surviving patients now have a median follow-up of 80.5 months (range, 44-142). The median progression-free survival is 78 months, and median overall survival has not been reached. Eighteen patients (46%) have relapsed. Neither histology nor prior low-grade oligodendroglioma correlated with risk of relapse. Persistent nonenhancing tumor at transplant was identified in our initial report as a significant risk factor for relapse; however, long-term follow-up has not confirmed this finding. Long-term neurotoxicity has developed only in those patients whose disease relapsed and required additional therapy; no patient in continuous remission has developed a delayed neurologic injury. This treatment strategy affords lo...Continue Reading
References
Feb 1, 1991·Archives of Neurology·J G Cairncross, D R Macdonald
Oct 15, 1994·International Journal of Radiation Oncology, Biology, Physics·D E GannettM S Berger
Oct 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G CairncrossC Schold
Jan 1, 1996·Neurology·W P MasonL M DeAngelis
Oct 1, 1996·Journal of Neurosurgery·L KimD N Louis
Dec 13, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M C Chamberlain, P A Kormanik
Jun 2, 1998·Medical and Pediatric Oncology·H S FriedmanA H Friedman
Oct 17, 1998·Journal of the National Cancer Institute·J G CairncrossD N Louis
Sep 25, 1999·Neurology·N A PaleologosJ G Cairncross
Feb 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J S SmithR B Jenkins
Dec 23, 2003·Journal of Neuro-oncology·Lauren E AbreyJ Gregory Cairncross
Mar 5, 2004·Expert Opinion on Pharmacotherapy·Riccardo Soffietti
Apr 10, 2004·Journal of Neuro-oncology·S ChibbaroR Gagliardi
Citations
Oct 13, 2006·Current Treatment Options in Oncology·Lyndon Kim, Michael Glantz
Jun 4, 2011·Neuro-oncology·Andrew B LassmanKatherine S Panageas
Oct 9, 2012·Neuro-oncology·Laura NegrettiChristelle Dufour
Nov 18, 2008·Journal of Pediatric Hematology/oncology·Jeong Ok Hah
Jan 3, 2009·PloS One·Magdalena BenetkiewiczOlivier Delattre
Sep 1, 2014·Seminars in Oncology·Kurt A Jaeckle
Jun 9, 2006·Expert Review of Anticancer Therapy·Jennifer I Stern, Jeffrey J Raizer
Oct 18, 2007·Expert Review of Neurotherapeutics·Riccardo SoffiettiRoberta Rudà
Sep 10, 2011·Revue neurologique·N Sanai, M S Berger
Oct 30, 2007·Neurologic Clinics·Martin J van den Bent
Feb 15, 2008·Critical Reviews in Oncology/hematology·Martin J Van den BentCharles Vecht
Nov 18, 2015·CNS Oncology·Martin J van den Bent
Feb 3, 2009·The Oncologist·Jacolien E C Bromberg, Martin J van den Bent
May 7, 2008·Journal of Neuro-oncology·Nimish A MohileLauren E Abrey
Feb 22, 2012·Journal of Neuro-oncology·Lauren E Abrey
Oct 27, 2014·Journal of Neuro-oncology·Walter TaalMartin J van den Bent
Dec 20, 2018·Journal of Neuro-oncology·Yasuo IwadateYoshinori Higuchi
May 5, 2017·Neuro-oncology·Alissa A ThomasAntonio Omuro